SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: idahoranch1 who wrote (47724)11/20/2018 11:15:38 PM
From: gary321  Read Replies (1) of 63276
 
Ignore Natural Killer cell therapy potential to render 132 obsolete at your own risk. If I remember correctly, Immu was around 2-3 dollars even as evidence was showing a breakthrough agent as late as 2016.

Keep in mind that study is only 14 months old, so data is not fully matured. ADC is extremely expensive to manufacture and to scale, therefore, something so cheap as Natural killer cells would be a transformational technology. The speed at which NK cells are catching on is incredible, Roche billion dollar pack with Affimed, Celgene Billion dollar deal with Dragonfly, all within the last month.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News